BC
NTLA icon

Bartlett & Co’s Intellia Therapeutics NTLA Stock Holding History

Bartlett & Co’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$6K Hold
200
– – ﹤0.01% 1059
2023
Q3 		$6K Hold
200
– – ﹤0.01% 975
2023
Q2 		$8K Hold
200
– – ﹤0.01% 945
2023
Q1 		$7K Hold
200
– – ﹤0.01% 853
2022
Q4 		$7K Hold
200
– – ﹤0.01% 873
2022
Q3 		$11K Hold
200
– – ﹤0.01% 810
2022
Q2 		$10K Hold
200
– – ﹤0.01% 863
2022
Q1 		$15K Buy
+200
New +$16.9K ﹤0.01% 768

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Bartlett & Co's NTLA Position: Q4 2023 in Review

Bartlett & Co held its Intellia Therapeutics (NTLA) position steady in Q4 2023 at 200 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #1059.

Bartlett & Co first reported a position in NTLA in Q1 2022 and has held it in 8 quarters since. The position peaked at $15K in Q1 2022. 292 funds tracked by Wall St. Rank hold NTLA as of Q4 2023.

  • Bartlett & Co held 200 shares of Intellia Therapeutics worth $6K as of Q4 2023.
  • Bartlett & Co left its Intellia Therapeutics share count unchanged in Q4 2023.
  • Intellia Therapeutics made up ﹤0.01% of Bartlett & Co's portfolio in Q4 2023, its #1059 holding.
  • Bartlett & Co first reported a position in Intellia Therapeutics in Q1 2022 and has held it in 8 quarters since.
  • Bartlett & Co's Intellia Therapeutics position peaked at $15K in Q1 2022.
  • 292 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2023.

Based on Bartlett & Co's 13F filing for Q4 2023, filed 8 Jan 2024.